Tuberculosis and Respiratory Diseases

  • 제58권4호
  • /
  • Pages.344-351
  • /
  • 2005
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

비소세포 폐암 환자의 이차 치료로서 Gemcitabine과 Vinorelbine 혼합 요법의 효과

Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase II Trial

  • 장필순 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 강현모 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 이정은 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 권선중 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 안진영 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 이연선 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 정성수 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 김주옥 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소) ;
  • 김선영 (충남대학교 의과대학 내과학교실, 충남대학교병원 암공동연구소)
  • Jang, Pil Soon (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Kang, Hyun Mo (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Lee, Jeong Eun (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Kwon, Seon Jung (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • An, Jin Young (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Lee, Yun Sun (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Jeong, Sung Soo (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Kim, Ju Ock (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute) ;
  • Kim, Sun Young (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
  • 투고 : 2005.01.17
  • 심사 : 2005.03.08
  • 발행 : 2005.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

배 경 : Gemcitabine, paclitaxel, docetaxel, vinorelbine, irrinotecan 새로운 항종양제의 출현으로 일차 치료의 효과가 증대 되고 있고 재발시에도 좋은 신체 활동도를 보이고 있어서 이차 치료의 대상군도 늘어나는 효과를 보이고 있다. 치료의 필요성은 증대 되고 있지만 현재까지 표준 치료가 확립되지 않은 상황에서 Gemcitabine과 Vinorelbine 모두 독성이 강하지 않아서 혼합 요법이 가능한 장점이 있고 비소세포폐암에 대한 효과도 입증이 되어있어서 본 연구는 반응이 없거나 반응을 보인후에 재발된 진행된 비소세포 폐암에 gemcitabine과 vinorelbine 혼합 요법을 시행하여서 치료 반응률과 생존율 그리고 부작용을 평가하였다. 대상 및 방법 : 2000년 6월부터 2004년 3월까지 충남대학교병원에 내원하여 진행성 비소세포 폐암 IIIA/IIIB, IV로 진단을 받고 일차 항암화학요법치료를 받은 환자중에 초기 치료에 반응이 없거나, 치료에 반응이 있었으나 병이 진행된 환자로 추적 관찰 기간이 6개월 이상인 환자를 대상으로 생존율과 반응률 그리고 독성을 분석하였다. 결 과 : 총 치료 반응률은 17%, 반응 유지기간의 중앙값은 3.1개월(1-10개월)이었고 생존기간의 중앙값은 8.2개월(1-23개월) 그리고 1년 생존율은 35%였다. 항암화학요법에 의한 독성은 3도 이상의 중성구 감소가 12%, 오심과 구토가 12.5% 였다. 결 론 : 일차 치료에 반응이 없거나 재발한 비소세포 폐암환자의 이차 치료로 gemcitabine과 vinorelbine 혼합요법은 효과적이라고 생각되며 향후 3상 연구를 통한 다른 약제와의 비교 연구가 필요하다고 생각된다.

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine $25mg/m^2$ followed by an infusion of gemcitabine $1000mg/m^2$ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI 1-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness.

키워드

참고문헌

  1. Kim SY, Kim GH. Rescent advances in lung cancer chemotherapy. Tuberc Respir Dis 2000;49:533-45 https://doi.org/10.4046/trd.2000.49.5.533
  2. le Chevalier T, Brisgard D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer. J Clin Oncol 1994;12:360-7 https://doi.org/10.1200/JCO.1994.12.2.360
  3. Sandler A, Ettinfer DS. Gemcitabine: single agent and combination therapy in non-small cell lung cancer. Oncologist 1999;4:241-51
  4. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients versus etoposide with cisplatin. J Clin Oncol 2000;18:623-31 https://doi.org/10.1200/JCO.2000.18.3.623
  5. Gatzemeier U, Shepherd FA, le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996;32A:243-8
  6. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40 https://doi.org/10.1200/JCO.1994.12.8.1535
  7. Crio L, Mosconi AM, Scagliotti G, Selvaggi G, Bovello S, Rinaldi M, et al. Gemcitabine as secondline treatment for advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1999;17:2081-5 https://doi.org/10.1200/JCO.1999.17.7.2081
  8. van Putten JW, Baas P, Codrington H, Kwa HB, Muller M, Aaronson N, et al. Activity of single-agent gemcitabine as seconde-line treatment after previous chemotherapy or radiotherapy in advanced non-small cell lung cancer. Lung Cancer 2001;33:289-98 https://doi.org/10.1016/S0169-5002(01)00188-X
  9. Green MR. Gemcitabine safety overview. Semin Oncol 1996;23:32-5
  10. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of vinorelbine in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9 https://doi.org/10.1097/00000421-199104000-00004
  11. Furuse K, Kubuto K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994;11:385-91 https://doi.org/10.1016/0169-5002(94)92167-9
  12. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996;22:127-42 https://doi.org/10.1016/S0305-7372(96)90032-8
  13. Lorusso V, Carpagnano F, Frasci G, Panza N, de Rienzo G, Cisternino ML, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol 2000;18:405-11 https://doi.org/10.1200/JCO.2000.18.2.405
  14. Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, et al. Vinorelbine/gemcitabine in advanced non-small cell lung cancer: a phase I trial. Eur J Cancer 1998;34:1977-80 https://doi.org/10.1016/S0959-8049(98)00235-4
  15. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994;12:1232-7 https://doi.org/10.1200/JCO.1994.12.6.1232
  16. Gatzemeier U, Heckmayr M, Neuhauss R, Schluter I, Pawel JV, Wagner H, et al. Phase II trial of paclitaxel for treatment of advanced inoperable nonsmall cell lung cancer. Lung Cacner 1995;12:S101-6
  17. Laack E, Mende T, Benk J, Chemaissani A, Scholtze J, Lorenz C, et al. Gemcitabine and vinorelbine as first-line therapy for non-small cell lung cancer: a phase II trial. Eur J Cancer 2001;37:583-90 https://doi.org/10.1016/S0959-8049(00)00441-X
  18. Kosmidis P, Mylonskis N, Fountzilas G, Samantas E, Athanasiadis A, Skarlos D. Paclitaxel and carboplatin in inoperable non-small cell lung cancer. Semin Oncol 1996;23:68-70
  19. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of nonsmall cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70 https://doi.org/10.1200/JCO.1995.13.8.1860
  20. Laack E, Dickgreber N, Muller T, Knuth A, Benk J, Lorenz C, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabin, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer. J Clin Oncol 2004;22:2348-56 https://doi.org/10.1200/JCO.2004.10.576
  21. Crino L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-5 https://doi.org/10.1200/JCO.1999.17.7.2081
  22. Reddy GR, Gandara DR, Edelman MJ. Gemcitabine in platinum treated non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:521
  23. Pronzato A, Landucci M, Vaira F, Vigani A, Bertelli G. Failure of vinorelbine to produce responses in prereated non-small cell lung cancer patients. Anti-cancer Res 1994;14:1413-5
  24. Fuks JZ, Egorin MJ, Aisner J, van Echo DA, Ostrow S, Bachur NR, et al. Therapeutic efficacy and pharmacokinetics of vindesine and of vindesin-cisplatin in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol 1983;10:104-8 https://doi.org/10.1007/BF00446219
  25. Socinski MA, Steagall A, Gillenwater H. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest 1999;17:181-8 https://doi.org/10.3109/07357909909021419
  26. Ruckdeschel J, Wagner HW. Second-line chemotherapy for resistant, metastatic non-small cell lung cancer:the role of taxol. Proc Am Soc Clin Oncol 1994;13:357
  27. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995;13:1609-14 https://doi.org/10.1200/JCO.1995.13.7.1609
  28. Hainsworth JD, Burris HA 3rd, Litchy S, Erland JB, Hon JK, Brierre JE, et al. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial. Cancer 2000;88:1353-8 https://doi.org/10.1002/(SICI)1097-0142(20000315)88:6<1353::AID-CNCR11>3.0.CO;2-A
  29. Herbst RS, Khuri FR, Jung M. Phase II study of combination weekly gemcitabine and vinorelbine in patients with previously treated non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:462a
  30. Camps C, Martinez EN, Jaime AB. Second-line treat- ment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53 https://doi.org/10.1016/S0169-5002(99)00092-6
  31. Camps C, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53 https://doi.org/10.1016/S0169-5002(99)00092-6
  32. Komas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, et al. Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane+pla-tinum-based regimens. Eur J Cancer 2001;37:972-8 https://doi.org/10.1016/S0959-8049(00)00419-6
  33. Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J. Phase II study of gemcitabine and vinorelbine combination therapy in patients with nonsmall cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol 2003;26:567-70 https://doi.org/10.1097/01.coc.0000045808.39041.49
  34. Kim YJ, Sohn JH, Kim C, Kim YT, Kim HJ, Ahn B, et al. Phase II study of gemcitabine and vinorelbine as second-line chemotherapy in non-small cell lung cancer. Cancer Res Trea 2003;35:294-8 https://doi.org/10.4143/crt.2003.35.4.294
  35. Park YH, Lee JC, Ryoo BY, Kim CH, Kim HT. Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol 2004;34:245-9 https://doi.org/10.1093/jjco/hyh043
  36. Androulakis N, Papadakis E, Bania E. Second-line treatment with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:491
  37. Androulakis N, Kouroussis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin or docetaxel-based chemotherapy: a multicenter phase II trial. Ann Oncol 1998;9:1127-30 https://doi.org/10.1023/A:1008497322508
  38. Hotton KM, Kim K, Larson ML. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer pre-viously treated with platinumbased chemotherapy. Proc Am Soc Clin Oncol 1999;18:509
  39. Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996;23:19-21
  40. Nakanishi Y, Takayama K, Takano K, Inoue K, Osaki S, Wataya H, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999;22:399-402 https://doi.org/10.1097/00000421-199908000-00016